BG
EIGR

Bellevue Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Bellevue Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-111
Closed -$39K – 135
2016
Q4 		$39K Hold
111
– – 0.01% 122
2016
Q3 		$45K Hold
111
– – 0.01% 121
2016
Q2 		$66K Hold
111
– – 0.01% 124
2016
Q1 		$56K Buy
+111
New +$55.3K 0.01% 128

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Bellevue Group's EIGR Position: Q1 2017 in Review

Bellevue Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2017, closing a stake of 111 shares — an estimated $39K sold.

Bellevue Group first reported a position in EIGR in Q1 2016 and held it in 4 quarters. The position peaked at $66K in Q2 2016. 45 funds tracked by Wall St. Rank hold EIGR as of Q1 2017.

  • Bellevue Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Bellevue Group sold 111 Eiger BioPharmaceuticals, Inc. shares in Q1 2017, an estimated $39K.
  • Bellevue Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2016 and held it in 4 quarters.
  • Bellevue Group's Eiger BioPharmaceuticals, Inc. position peaked at $66K in Q2 2016.
  • 45 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2017.

Based on Bellevue Group's 13F filing for Q1 2017, filed 11 May 2017.